Inventor · disambiguated record
Mihalis Kariolis
Also filed as: KARIOLIS MIHALIS · KARIOLIS MIHALIS S
24 granted patents·28 pending applications·113 citations·filing 2010–2025
95Inventor score
Files withDENALI THERAPEUTICS INC30UNIV LELAND STANFORD JUNIOR17COCHRAN JENNIFER R2GIACCIA AMATO J2ARAVIVE BIOLOGICS INC1
Top patents by PatentIndex Score
52 records- 0196US11912778B2Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2022·Granted Feb 27, 2024·2 cites·17 claims
- 0295US11498952B2Fusion proteins comprising an engineered knottin peptide and uses thereofUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Nov 15, 2022·4 cites·3 claims
- 0395US11124567B2Anti-TREM2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Sep 21, 2021·16 cites·31 claims
- 0495US10457717B2Engineered polypeptidesDENALI THERAPEUTICS INC·Filed 2018·Granted Oct 29, 2019·11 cites·29 claims
- 0594US12240882B2Fusion proteins comprising an engineered knottin peptide and uses thereofUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Mar 4, 2025·2 cites·14 claims
- 0693US12162948B2Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Granted Dec 10, 2024·1 cites·16 claims
- 0793US10870837B2Fusion proteins comprising enzyme replacement therapy enzymesDENALI THERAPEUTICS INC·Filed 2019·Granted Dec 22, 2020·9 cites·47 claims
- 0891US11884944B2Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereofDENALI THERAPEUTICS INC·Filed 2022·Granted Jan 30, 2024·2 cites·39 claims
- 0991US8618254B2Inhibition of AXL signaling in anti-metastatic therapyGIACCIA AMATO J·Filed 2012·Granted Dec 31, 2013·25 cites·8 claims
- 1090US10588938B2Receptor-based antagonists of the programmed cell death 1 (PD-1) pathwayUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Mar 17, 2020·8 cites·4 claims
- 1189US11866742B2Fusion proteins comprising enzyme replacement therapy enzymesDENALI THERAPEUTICS INC·Filed 2020·Granted Jan 9, 2024·2 cites·35 claims
- 1288US11795232B2Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2019·Granted Oct 24, 2023·2 cites·38 claims
- 1388US9074192B2Inhibition of AXL signaling in anti-metastatic therapyGIACCIA AMATO J·Filed 2012·Granted Jul 7, 2015·7 cites·7 claims
- 1488US2024141058A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1587US2024018253A1Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1685US2025297023A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1784US8778888B2Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of useCOCHRAN JENNIFER R·Filed 2010·Granted Jul 15, 2014·4 cites·20 claims
- 1883US9879061B2Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosisUNIV LELAND STANFORD JUNIOR·Filed 2012·Granted Jan 30, 2018·4 cites·4 claims
- 1982US10844106B2Fusion proteins comprising an engineered knottin peptide and uses thereofCOCHRAN JENNIFER R·Filed 2011·Granted Nov 24, 2020·3 cites·24 claims
- 2082US2024024432A1Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2182US2024271326A1Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2279US11136563B2Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Oct 5, 2021·1 cites·6 claims
- 2379US10876176B2Antifibrotic activity of GAS6 inhibitorARAVIVE BIOLOGICS INC·Filed 2015·Granted Dec 29, 2020·2 cites·4 claims
- 2479US9266947B2Inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Granted Feb 23, 2016·4 cites·6 claims
- 2578US9822347B2Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Granted Nov 21, 2017·3 cites·3 claims
- 2678US2025367284A1Anti-transferrin receptor fusion proteins and methods of use thereofDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2778US2025387477A1Anti-transferrin receptor fusion proteins and methods of use thereofDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2876US2023381286A1Affinity-based methods for using transferrin receptor-binding proteinsDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2975US11498955B2SPD-1 variant# FC fusion proteinsUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Nov 15, 2022·1 cites·38 claims
- 3073US2024150736A1Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereofDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3171US2022378873A1Receptor-based antagonists of the programmed cell death 1 (pd-1) pathwayUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 3269US2022220458A1Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic TherapyUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3368US11400133B2Receptor-based antagonists of the programmed cell death 1 (PD-1) pathwayUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Aug 2, 2022·0 cites·20 claims
- 3467US11732023B2Engineered polypeptidesDENALI THERAPEUTICS INC·Filed 2019·Granted Aug 22, 2023·0 cites·17 claims
- 3567US2024148866A1Anti-transferrin receptor fusion proteins and methods of use thereofDENALI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3667US2020369746A1Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3765US2023131056A1sPD-1 VARIANT – FC FUSION PROTEINSUNIV LELAND STANFORD JUNIOR·Filed 2022·Application pending·0 cites
- 3864US2020289627A1Affinity-based methods for using transferrin receptor-binding proteinsDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3962US2022177576A1Anti-trem2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4061US2024299575A1Oligonucleotide conjugates targeted to the transferrin receptorDENALI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4160US2025145729A1Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4259US2020277584A1Fusion proteins comprising enzyme replacement therapy enzymesDENALI THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4356US2025136963A1Fusion proteins comprising alpha-l-iduronidase enzymes and methodsDENALI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4452US12378540B1Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereofDENALI THERAPEUTICS INC·Filed 2025·Granted Aug 5, 2025·0 cites·17 claims
- 4552US2021130485A1Transferrin receptor-binding polypeptides and uses thereofDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4651US2022184186A1Formulations of protein molecules comprising iduronate 2-sulfataseDENALI THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4751US2018094034A1Inhibition of axl/gas6 signaling in the treatment of liver fibrosisUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 4847US2015315552A1Inhibition of AXL Signaling in Primary Tumor TherapyUNIV LELAND STANFORD JUNIOR·Filed 2013·Application pending·0 cites
- 4947US2016266136A1High-affinity binding to gas6UNIV LELAND STANFORD JUNIOR·Filed 2013·Application pending·0 cites
- 5047US2016108378A1Inhibition of AXL Signaling in Anti-Metastatic TherapyUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →